From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Infectious Diseases

Highly Sensitive Epigenomic Technology Combats Disease

Virginia Tech researchers develop method to produce a profile of histone modifications using as few as 100 cells per assay.

by Global Biodefense Staff
December 4, 2019
Highly Sensitive Epigenomic Technology Combats Disease

Left to right, Bohan Zhu, Yuan-Pang Hsieh, and Chang Lu. Credit: Virginia Tech

In a recently published article in Nature Protocols, a team of researchers from Virginia Tech outline a new technology to help in understanding how the human body battles diseases.

Much remains unknown about diseases and the way our bodies respond to them, in part because the human genome is the complete DNA assembly that makes each person unique. Chang Lu, the Fred W. Bull Professor of Chemical Engineering at Virginia Tech, along with chemical engineering doctoral students Bohan Zhu and Yuan-Pang Hsieh, describe a microfluidic technology they are using to study a variety of diseases ranging from breast and brain cancer to schizophrenia and addiction.

The new technology developed includes detailed instructions for device fabrication, setup, and operation of microfluidic oscillatory washing-based chromatin immunoprecipitation followed by a sequencing method called MOWChIP-seq, a low-input technology that allows characterization of the epigenome using as few as 100 cells.

The method is novel because up until now, conventional methods required tens of millions of cells per assay. But by using the new sequencing method, the team has discovered they can produce a profile of histone modifications using as few as 100 cells per assay with a throughput as high as eight assays in one run.

“By comparing normal and diseased epigenomes, useful markers and patterns can be discovered and used for precision medicine based on epigenomic features of an individual patient,” Lu said.

This research builds upon Lu’s previous work in developing the MOWChIP-seq, first published in a Nature Methods paper in 2015. A U.S. patent was awarded to Lu and his former doctoral student, Zhenning Cao, for their work. Compared to their original 2015 publication, in the current protocol Lu and his team detailed their recent effort on automating the MOWChIP-seq process and processing eight samples in parallel in one run.

The team’s process is semi-automated and reduces labor and improves reproducibility and is scalable.

Lu’s research is supported by the National Cancer Institute, the National Institute of Biomedical Imaging and Bioengineering, the National Human Genome Research Institute of the National Institutes of Health, and the Virginia Tech Institute for Critical Technology and Applied Science’s Center for Engineered Health.

From Our Partners
Tags: Genomics

Related Posts

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America
Infectious Diseases

Chronic Wasting Disease: The Fatal Prion Infection Killing Elk and Deer in North America

June 10, 2022
Transforming How We Think About Sepsis
Infectious Diseases

Transforming How We Think About Sepsis

June 10, 2022
Congenital Syphilis Continues a Decade-Long Surge Across the US
Infectious Diseases

Congenital Syphilis Continues a Decade-Long Surge Across the US

April 12, 2022
Send in the Blow Flies: Using Insects to Sample Areas for Chemical Warfare Agents
CBRNE

Send in the Blow Flies: Using Insects to Sample Areas for Chemical Warfare Agents

April 11, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC